Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR

Squarepoint Ops LLC raised its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 3,150.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 363,153 shares of the biopharmaceutical company’s stock after purchasing an additional 351,979 shares during the period. Squarepoint Ops LLC owned 0.51% of Xencor worth $2,854,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Primecap Management Co. CA grew its stake in shares of Xencor by 7.9% in the 2nd quarter. Primecap Management Co. CA now owns 10,527,322 shares of the biopharmaceutical company’s stock worth $82,745,000 after buying an additional 766,310 shares during the last quarter. BVF Inc. IL raised its stake in Xencor by 19.7% during the first quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock valued at $29,155,000 after buying an additional 451,381 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Xencor by 1.8% in the second quarter. Geode Capital Management LLC now owns 1,703,664 shares of the biopharmaceutical company’s stock worth $13,393,000 after acquiring an additional 29,316 shares during the last quarter. Braidwell LP increased its holdings in shares of Xencor by 169.0% during the first quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company’s stock valued at $17,617,000 after acquiring an additional 1,040,159 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Xencor by 94.5% during the second quarter. Bank of America Corp DE now owns 938,993 shares of the biopharmaceutical company’s stock valued at $7,380,000 after acquiring an additional 456,302 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on XNCR. Barclays upped their price target on shares of Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday. Bank of America downgraded shares of Xencor from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Cantor Fitzgerald raised their price target on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Truist Financial assumed coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Royal Bank Of Canada increased their target price on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and a consensus price target of $24.88.

Xencor Stock Down 4.5%

XNCR opened at $15.80 on Thursday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -8.93 and a beta of 0.96. The firm has a 50 day moving average price of $15.26 and a 200-day moving average price of $11.13. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $25.52.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.64. The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $29.73 million. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.71) earnings per share. As a group, analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.